Cullinan Oncology Inc. on Tuesday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to CLN-081 for the treatment of certain patients with non-small cell lung cancer.
The Cambridge, Mass., biopharmaceutical company said the designation covers CLN-081 in patients with locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor exon 20 insertion mutations who have previously received platinum-based systemic chemotherapy.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.
Cullinan is evaluating various doses of CLN-081 in a Phase 1/2a trial in patients harboring exon 20 mutations whose disease has progressed on or after prior therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.